WO2025237212 - PYRIMIDINE DERIVATIVE MEGLUMINE SALT AND CRYSTAL FORMS THEREOF
National phase entry is expected:
Publication Number
WO/2025/237212
Publication Date
20.11.2025
International Application No.
PCT/CN2025/094126
International Filing Date
10.05.2025
Title **
[English]
PYRIMIDINE DERIVATIVE MEGLUMINE SALT AND CRYSTAL FORMS THEREOF
[French]
SEL DE MÉGLUMINE DÉRIVÉ DE PYRIMIDINE ET FORMES CRISTALLINES DE CELUI-CI
[Chinese]
一种嘧啶衍生物葡甲胺盐及其晶型
Applicants **
GUANGDONG RAYNOVENT BIOTECH CO., LTD
Inventors
LIU, Chengwu
ZHOU, Guangqiang
CAI, Zemian
XIE, Deqin
LIU, Zhuowei
CHEN, Xiaoxin
Priority Data
202410585632.2
11.05.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1576 | |
| EPO | Filing, Examination, Granting | 11576 | |
| Japan | Filing, Examination, Granting | 1970 | |
| South Korea | Filing, Examination, Granting | 1739 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
21,601
Contact Us
Abstract[English]
Disclosed for the first time are a pyrimidine derivative meglumine salt as shown below and crystal forms thereof. A series of the crystal forms exhibits good developability (such as stability, fluidity, compressibility, solubility, bioavailability, etc.), providing a variety of bulk drug options for subsequent drug development.[French]
La présente invention concerne, pour la première fois, un sel de méglumine dérivé de pyrimidine tel que représenté ci-dessous et des formes cristallines de celui-ci. Une série des formes cristallines présente une bonne aptitude au développement (telle que la stabilité, la fluidité, la compressibilité, la solubilité, la biodisponibilité, etc.), constituant diverses options d'ingrédients pharmaceutiques actifs pour la mise au point ultérieure de médicaments.[Chinese]
本发明首次公开一种如下所示嘧啶衍生物的葡甲胺盐及其晶型，该系列晶型表现为具有较好的成药性(如稳定性、流动性、可压性、溶解度、生物利用度等)，为后续药品开发提供多种原料药选择。